文献速递淋巴瘤

基于中期PET/CT调整早期和晚期霍奇金淋巴瘤的初始治疗有益:一项355例患者的前瞻性多中心试验

Modification of initial therapy in early and advanced Hodgkin lymphoma, based on interim PET/CT is beneficial: a prospective multicentre trial of 355 patients.
PubMed 文献 · Br J Haematol · 2017-06-07

这项前瞻性多中心试验在以色列九家中心纳入359例18-60岁霍奇金淋巴瘤患者,依据初始预后因素及两周期后PET/CT(PET-2)个体化调整治疗,中位随访55个月。早期HL中PET-2阳性者5年PFS为69%、阴性者为91%;晚期HL中PET-2阳性者5年PFS为68%、阴性者为81%(P=0.08)。

要点

  • 早期HL中PET-2阳性与较差预后相关,即使追加ABVD和ISRT。
  • 晚期HL患者PET-2阳性后治疗升级可获益。
  • PET-2阴性的晚期HL患者可将EB安全降阶梯为ABVD。

核心结论

  • 早期HL中PET-2阳性与较差预后相关,即使追加ABVD和ISRT。
  • 晚期HL患者PET-2阳性后治疗升级可获益。
  • PET-2阴性的晚期HL患者可将EB安全降阶梯为ABVD。

研究设计与样本

  • 前瞻性多中心试验,2006年9月至2013年8月在以色列九家中心纳入359例18-60岁霍奇金淋巴瘤患者。
  • 依据初始预后因素及两周期后PET/CT(PET-2)结果个体化调整治疗。

主要发现

  • 中位随访55(13-119)个月,早期HL中PET-2阴性者5年PFS为91%、阳性者为69%;5年OS分别为100%和95%。
  • 晚期HL中PET-2阴性者5年PFS为81%、阳性者为68%(P=0.08);5年OS分别为98%和91%。

关键数值与推荐

  • 早期HL初始接受ABVD×2;PET-2阳性者追加ABVD后行累及部位放疗(ISRT)。
  • 早期HL中PET-2阴性且预后良好者接受ISRT或ABVD×2;预后不良者接受ABVD×2联合ISRT或ABVD×4。
  • 晚期HL依据国际预后评分(≤2或≥3)初始接受ABVD×2或 escalated BEACOPP(EB)×2。
  • 晚期HL中PET-2阴性者继续ABVD×4;PET-2阳性者接受EB×4并对残留肿块行ISRT。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This multicentre study evaluated 5-year progression-free (PFS) and overall survival (OS) in early and advanced Hodgkin lymphoma (HL), where therapy was individualized based on initial prognostic factors and positron emission tomography-computed tomography performed after two cycles (PET-2). Between September 2006 and August 2013, 359 patients aged 18-60 years, were recruited in nine Israeli centres. Early-HL patients initially received ABVD (adriamycin, bleomycin, vinblastine, dacarbazine) ×2. Depending on initial unfavourable prognostic features, PET-2-positive patients received additional ABVD followed by involved-site radiotherapy (ISRT). Patients with negative PET-2 and favourable disease received ISRT or ABVD ×2; those with unfavourable disease received ABVD ×2 with ISRT or, alternatively, ABVD ×4. Advanced-HL patients initially received ABVD ×2 or escalated BEACOPP (bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, prednisone; EB) ×2 based on their international prognostic score (≤2 or ≥3). PET-2-negative patients further received ABVD ×4; PET-2-positive patients received EB ×4 and ISRT to residual masses. With a median follow-up of 55 (13-119) months, 5-year PFS was 91% and 69% for PET-2-negative and positive early-HL, respectively; 5-year OS was 100% and 95%, respectively. For advanced-HL, the PFS was 81% and 68%, respectively (P = 0·08); 5-year OS was 98% and 91%, respectively. PET-2 positivity is associated with inferior prognosis in early-HL, even with additional ABVD and ISRT. Advanced-HL patients benefit from therapy escalation following positive PET-2. EB can be safely de-escalated to ABVD in PET-2-negative patients.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Dann EJ, Bairey O, Bar-Shalom R, et al. Modification of initial therapy in early and advanced Hodgkin lymphoma, based on interim PET/CT is beneficial: a prospective multicentre trial of 355 patients. Br J Haematol. 2017. PMID: 28589704. doi:10.1111/bjh.14734

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。